Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 6/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12879975 | 0.90 | ALDH1A1 (0.58) | ALDH1A1TSHRMAPTTP53HTT | |
| SCHEMBL12864966 | 0.90 | ALDH1A1 (0.58) | ALDH1A1TSHRMAPTTP53HTT | |
| SCHEMBL12864987 | 0.90 | ALDH1A1 (0.47) | ALDH1A1TSHRMAPTMAPK1TP53 | |
| SCHEMBL12903845 | 0.88 | ALDH1A1 (0.51) | ALDH1A1TSHRMAPTMAPK1TP53 | |
| SCHEMBL13319973 | 0.81 | MAPT (0.39) | ALDH1A1TSHRMAPTMAPK1TP53 | |
| SCHEMBL1170999 | 0.81 | MAPT (0.39) | ALDH1A1TSHRMAPTMAPK1TP53 | |
| SCHEMBL13319975 | 0.75 | TP53 (0.38) | ALDH1A1TSHRMAPTTP53HTT | |
| SCHEMBL12880233 | 0.75 | ALDH1A1 (0.45) | ALDH1A1TSHRMAPTTP53HTT | |
| SCHEMBL12865129 | 0.73 | MAPT (0.39) | ALDH1A1TSHRMAPTMAPK1TP53 | |
| SCHEMBL1171136 | 0.72 | MAPT (0.45) | ALDH1A1TSHRMAPTTP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034434-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2011-02-10 | — | — | US | disclosed |
| WO-2011017634-A2 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACORE INC. (US) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034434-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | DDO, DAO, AOC1 | ALDH1A1 350/4885TSHR 2891/4885MAPT 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.